DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2661 | Idr-0081053 | Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations |
|
| DCC2662 | Idr-0099118 | Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions |
|
| DCC2663 | Idr-1002 | Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin |
|
| DCC2664 | Idr-1018 Tfa Salt | Novel immunomodulatory and antibiofilm innate defense regulator peptide |
|
| DCC2665 | Idrapril | Angiotensin converting enzyme (ACE) inhibitor |
|
| DCC2666 | Iferanserin | Selective serotonin 5-HT2A receptor antagonist |
|
| DCC2667 | Ifn-1 Inducer C3 | Novel Type I Interferon Inducer |
|
| DCC2668 | Ifn-1 Inducer E51 | Novel Type I Interferon Inducer |
|
| DCC2669 | Ifn-1 Inducer L56 | Novel Type I Interferon Inducer; Intercalator of DNA; Inhibitor of the retrovirus replications including HIV |
|
| DCC2670 | Igf2bp2/imp2 Inhibitor 4 | First Small-Molecule Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2671 | Igf2bp2/imp2 Inhibitor 6 | Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2672 | Igf2bp2/imp2 Inhibitor 9 | Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy |
|
| DCC2673 | Iglu-antagonist-21a | Highly potent fluorescent iGlu receptor antagonist |
|
| DCC2674 | Ihr-saha | Novel dual SMO-HDAC antagonist, retaining similar specificity for SAHA-targeted HDACs, disabling deviant Hedgehog signaling and preventing GLI binding to DNA |
|
| DCC2675 | Ikarugamycin | Natural Inhibitor of Clathrin-Mediated Endocytosis |
|
| DCC2676 | Ikkß-in-124 | Novel allosteric inhibitor of IκBα phosphorylation and NF-κB transcriptional activity through selective capture of the inactive conformation and hence blockade of IKKβ S177/S181 phosphorylation |
|
| DCC2677 | Ilmofosine | Antineoplastic phospholipid, being effective against many tumor types, including ovary, non-small cell lung, kidney, and melanoma, exhibiting competitive inhibition of protein kinase C (PKC) activity |
|
| DCC2678 | Iloperidone Hydrochloride | Dual D 2 /5-HT 2 antagonist as an antipsychotic agent |
|
| DCC2679 | Imarikiren Dihydrochloride | Novel orally effective direct renin inhibitor for treating diabetic nephropathy and hypertension |
|
| DCC2680 | Imb-xma0038 | Novel anti-tuberculosis agent, targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase |
|
| DCC2681 | Imb-yh-8 | Novel inhibitor of protein kinase B (PknB), inhibiting PknB auto-phosphorylation and the phosphorylation of GarA by PknB in a dose-dependent manner |
|
| DCC2682 | Imc-48 | BCL2 i-motif-interactive compound, stabilizing or facilitating the folding of the i-motif |
|
| DCC2683 | Imc-76 | BCL2 i-motif-interactive compound, destabilizing or unfolding the i-motif |
|
| DCC2684 | Imidacloprid | Insect neurotoxin, blocking nicotinic acetylcholine receptors and preventing acetylcholine from transmitting impulses between nerves |
|
| DCC2685 | Imm-h004 | Novel potent inhibitor of BV2 microglia activation, protecting PC12 cells and primary neurons against indirect toxicity mediated by exposure to conditioned medium (CM) from LPS-treated BV2 cells |
|
| DCC2686 | Imp-1002 | Novel resistance breaking antimalarial N-myristoyltransferase (NMT) inhibitor, binding to NMT peptide binding pocket |
|
| DCC2687 | Imp-1700 | Novel cell-active and potent inhibitor of bacterial DNA repair, potentiating quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus |
|
| DCC2688 | Imp2070 | Novel Probe for NLRP3 Inflammasome Inhibitor MCC950 |
|
| DCC2689 | Impdh-in-1 | First in-class allosteric inhibitor of a bacterial IMPDH, showing to counteract the activation by the natural positive effector, MgATP, and to block the enzyme in its apo conformation |
|
| DCC2690 | Imprimatin-c1 | Novel plant immune-priming agent, acting as a partial agonist of salicylic acid |
|
